

July 14, 2023

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai: 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai: 400 051

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sirs,

**Sub: Statement of Investor Complaints**

Pursuant to Regulation 13 (3) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find below the statement of Investor complaints for the quarter ended June 30, 2023:

Sr. No	Particulars	Details
1	No. of Investor Complaints pending at the beginning of the quarter	00
2	No. of Investor Complaints received during the quarter	03
3	No. of Investor Complaints disposed off during the quarter	03
4	No. of Investor Complaints those remaining unresolved at the end of the quarter	00

Please take the same on records.

Yours Faithfully,

**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)